Pharmaceuticals Company Releases Positive Preclinical Study Data For Neurological Disorder Treatment
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action.
Disclaimer: The information provided in this article is based on the latest preclinical study data released by MIRA Pharmaceuticals. This article is for informational purposes only and should not be construed as medical advice. Readers are encouraged to consult healthcare professionals for any medical concerns or decisions.
Real-t…